---
title: "Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286234281.md"
description: "Bank of America Securities analyst Alec Stranahan has reaffirmed a Buy rating for Agios Pharma (AGIO) with a price target of $41.00, while the shares closed at $28.42. Stranahan, who focuses on the Healthcare sector, has an average return of 10.3% and a success rate of 52.78%. Additionally, Agios Pharma received a Buy rating from Truist Financial, while RBC Capital maintained a Hold rating."
datetime: "2026-05-13T09:38:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286234281.md)
  - [en](https://longbridge.com/en/news/286234281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286234281.md)
---

# Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Agios Pharma yesterday and set a price target of $41.00. The company’s shares closed yesterday at $28.42.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Beam Therapeutics, and Revolution Medicines. According to TipRanks, Stranahan has an average return of 10.3% and a 52.78% success rate on recommended stocks.

In addition to Bank of America Securities, Agios Pharma also received a Buy from Truist Financial’s Gregory Renza in a report issued on April 30. However, on April 29, RBC Capital maintained a Hold rating on Agios Pharma (NASDAQ: AGIO).

### Related Stocks

- [AGIO.US](https://longbridge.com/en/quote/AGIO.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances](https://longbridge.com/en/news/286947828.md)
- [47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D](https://longbridge.com/en/news/285910345.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/286913304.md)